Evidence map›Paper›PMID 39096426›Full record

SynthesisQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2024

The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Xinyue Zhang, Wai Kei Tong, Qian Xia, Zhijia Tang

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07452913 (Comparative Efficacy and Safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin as Initial Triple Therapy in Type 2 Diabetes Mellitus), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07452913 phase4enrolling by invitationstarted 2026, after this paper: background citation

Comparative Efficacy and Safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin as Initial Triple Therapy in Type 2 Diabetes Mellitus

Ran2026Enrolled110Registered outcomes5Posted comparisons0ConditionsType 2 Diabetes MellitusArmsMetformin + Empagliflozin + Linagliptin, Metformin+ Empagliflozin + Sitagliptin
PMID 37414069PMID 37294638PMID 35307801PMID 11953758PMID 39723311PMID 39596449PMID 39353925PMID 39030553PMID 38423026other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xinyue ZhangDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Pudong New District, Shanghai, 201203, China.ORCID http://orcid.org/0000-0002-5595-1917
Wai Kei TongDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Pudong New District, Shanghai, 201203, China.ORCID http://orcid.org/0000-0003-1519-4357
Qian XiaDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Pudong New District, Shanghai, 201203, China.
Zhijia TangDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Pudong New District, Shanghai, 201203, China. zjtang@fudan.edu.cn.ORCID http://orcid.org/0000-0001-8260-0082

Funding

Shanghai Municipal Health Commission 20194Y0234
6 · The paper itself

Abstract

purposeTo evaluate the impact of dipeptidyl peptidase 4 (DPP-4) inhibitors on Health-related quality of life (HRQOL) in patients with type 2 diabetes mellitus (T2DM) compared with other hypoglycemic agents.

methodsA systematic review and meta-analysis based on randomized controlled trials was conducted following the Cochrane Handbook and PRISMA. Studies were identified by searching PubMed (MEDLINE), EMBASE, Web of Science, CNKI, WANGFANG DATA, VIP DATABASE, Google Scholar, and Cochrane Central Register of Controlled Trials from database inception to Dec 30, 2023. The main result was HRQOL scores. The outcomes were extracted using the mean difference (MD) from each study. Sensitivity analysis and subgroup analysis were also performed.

resultsForty studies (4,579 participants) were included, with 32 pooled for meta-analysis. DPP-4 inhibitors alongside conventional treatment significantly enhanced HRQOL compared to conventional treatment alone (MD = 9.85, 95% CI [7.98-11.71], P < 0.001; heterogeneity, I

conclusionsDPP-4 inhibitors were superior for T2DM HRQOL improvement. More long-term, multicenter evidence is needed to generalize findings and compare them with newer hypoglycemic agents. SYSTEMATIC REVIEW REGISTRATION: PROSPERO: CRD42023440134.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsQuality of LifeHumansHypoglycemic AgentsRandomized Controlled Trials as TopicDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsDipeptidyl peptidase 4 inhibitorsHealth-related quality of lifeMeta-analysisSystematic reviewType 2 diabetes mellitus

Identifiers

PMID39096426

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.